Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Serum chitotriosidase levels appear to be useful in predicting a poor prognosis in patients with antimelanoma differentiation-associated gene 5 antibody (anti-MDA5)–positive dermatomyositis (DM)/clinically amyopathic DM-associated interstitial lung disease (DM/CADM-ILD), suggests a study.
Ultrasound may provide valuable information for the differential diagnosis of acute erosive arthritis, with a recent study showing that subcutaneous tissue changes and periosteal vascularity are more common in acute osteomyelitis (OM), whereas periosteal tophaceous material distinguishes gouty arthritis from acute OM and rheumatoid arthritis.
Undergoing bariatric surgery does not appear to mitigate the risk of rheumatoid arthritis among individuals with obesity, as reported in a recent study.
Belimumab for systemic lupus erythematosus (SLE) has demonstrated a stable safety profile over 8 years of follow-up, with no new safety signal and minimal organ damage progression, according to data from an extension study involving non-American patients who completed the phase III BLISS*-52 or BLISS-76 trials.
The high‐purity synthetic trans‐capsaicin CNTX‐4975 provides dose-dependent reduction in knee osteoarthritis (OA)-associated pain, as shown in the results of a phase II study.
High physical activity levels reduce the risk of developing rheumatoid arthritis in women, a study has found.
Concomitant use of conventional synthetic disease-modifying antirheumatic drug (csDMARD) results in a significantly lower risk for discontinuation of biologic (b)DMARD because of adverse events (AEs) among patients with rheumatoid arthritis (RA), according to a recent study.
Special Reports
With the objective of establishing a Malaysian consensus on the use of topical NSAIDs in the management of musculoskeletal pain, this meeting brought together experts from various backgrounds, ie, rheumatology, pharmacy, orthopaedics and general medicine. At the meeting, Dr Mary Suma Cardosa delivered a talk on the pathophysiology and effective management of pain, while the lecture by Dr Yeap Swan Sim focused on the management of musculoskeletal and soft-tissue pain. This article presents excerpts from the expert meeting and features the consensus statements agreed during the meeting.
At the 47th Annual Scientific Meeting/Annual General Meeting of the Malaysian Orthopaedic Association, Dr Algis Jovaisas discussed important clinical considerations when it comes to choosing between nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) and selective COX-2 inhibitors (coxibs) for the management of acute pain.
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
Conference Reports
Privacy and transparency are among the core points to consider when utilizing big data in rheumatic and musculoskeletal disorders (RMDs), according to the first EULAR-endorsed recommendations for use of big datasets in research.
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
Patients with painful hand osteoarthritis can finally get relief from pain with low-dose prednisolone, suggests a study presented at EULAR 2019.
Occupational exposure to inorganic dust, particularly asbestos, silica, and coal, was associated with an increased risk of developing gout, according to a study presented at EULAR 2019.
Being overweight may have an impact on disease severity in psoriatic arthritis, according to a study presented at EULAR 2019.
The selective Janus kinase 1 inhibitor upadacitinib demonstrated sustained efficacy and safety beyond 12 weeks in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response or were refractory to disease-modifying antirheumatic drugs (DMARDs), according to the interim results of the ongoing extension phases of SELECT-NEXT* and SELECT-BEYOND** presented at EULAR 2019.
Both inflammatory bowel disease (IBD) and type 1 diabetes (T1D) are highly prevalent among patients who eventually develop rheumatoid arthritis (RA), indicating that these two conditions are potential risk factors for RA, according to a study presented at EULAR 2019.
